Title: Ketamine and the pursuit of rapid-acting antidepressants for the treatment of depression and PTSD symptoms.

**Abstract**

The limitations of standard antidepressant treatments are well known, they work for too few patients and their beneficial effects emerge too slowly. APPROACH: The purpose of this presentation is to briefly describe the context leading to the discovery of the antidepressant effects of ketamine in humans, to characterize our current understanding of the profile of ketamine's efficacy and ways that it is entering routine clinical treatment, to consider the management of risks associated with ketamine treatment, and to consider emerging alternatives to ketamine. Emerging studies also point to ketamine effectiveness in PTSD. CONCLUSIONS: The rapidity (onset within 24 hours) and magnitude (50%-75% clinical response rate, even in treatment-resistant depression populations) of the efficacy of ketamine suggest that it could be a new and important role in the treatment of mood disorders where clinical response is needed urgently or where there has been inadequate response to other treatments.

Disclosure: Dr. Krystal is a co-proponent of a use patent related to the intranasal administration of ketamine for the treatment of depression that has been licensed by Johnson and Johnson.
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